Home › Non-Small Cell Lung Cancer › Maryland › Baltimore
Pag-aaral pangklinika para sa Non-Small Cell Lung Cancer sa Baltimore, MD
Isang pag-aaral para sa Non-Small Cell Lung Cancer ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Baltimore. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Nagre-recruitPhase 3
- Greater Baltimore Medical Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore
- at 4 pa
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Nagre-recruitPhase 2
- Local Institution - 0123, Baltimore
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
Nagre-recruitPhase 3
- Ascension Saint Agnes Hospital, Baltimore
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
Nagre-recruitPhase 1/2
- Research Site, Baltimore
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Nagre-recruitPhase 1
- Exelixis Clinical Site #14, Baltimore
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
Nagre-recruitPhase 2
- MedStar Franklin Square Medical Center ( Site 0033), Baltimore
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Nagre-recruitPhase 2
- Johns Hopkins University, Baltimore
DK222 Study at Hopkins
Nagre-recruitPhase 1
- Johns Hopkins Hospital, Baltimore
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Nagre-recruitPhase 3
- Johns Hopkins University of Medicine, Baltimore
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Nagre-recruitPhase 2
- Sidney Kimmel Cancer Center - Bayview Campus, Baltimore
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Nagre-recruitPhase 3
- Maryland Oncology Hematology, P.A., Annapolis · 22 mi ang layo
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Nagre-recruitPhase 3
- Research Site, Towson · 8 mi ang layo
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Nagre-recruitPhase 3
- Maryland Oncology Hematology, P.A., Annapolis · 22 mi ang layo
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Nagre-recruitPhase 2
- University of Maryland, Baltimore
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Nagre-recruitPhase 2
- University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Nagre-recruitPhase 3
- University of Maryland, Baltimore
- Johns Hopkins Bayview Medical Center, Baltimore
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Nagre-recruitPhase 3
- Research Site, Annapolis · 22 mi ang layo
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Nagre-recruitPhase 2
- Research Site, Baltimore
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Nagre-recruitPhase 3
- Local Institution - 0505, Annapolis · 22 mi ang layo
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Nagre-recruitPhase 3
- Local Institution - 0702, Annapolis · 22 mi ang layo
Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
Nagre-recruitPhase 2
- University of Maryland Greenebaum Cancer Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- Medstar Franklin Square, Baltimore
- at 1 pa
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Nagre-recruitPhase 3
- Clinical Study Site, Baltimore
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Nagre-recruitPhase 1
- Johns Hopkins, Baltimore
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
Nagre-recruitPhase 1
- United Theranostics, Glen Burnie · 9 mi ang layo
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Nagre-recruitPhase 2/3
- The Sidney Kimmel Comprehensive Cancer Center, Baltimore
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
Nagre-recruitPhase 2
- John Hopkins Medical Center, Baltimore
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Nagre-recruitPhase 3
- Johns Hopkins Bayview Medical Center, Baltimore
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Nagre-recruitPhase 3
- Saint Agnes Hospital - Baltimore - Hunt - PPDS, Baltimore
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Nagre-recruitPhase 3
- Research Site, Baltimore
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Nagre-recruitPhase 1
- University of Maryland Marlene & Stewart Greenebaum Comprehensive Cancer Center, Baltimore
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
Nagre-recruitPhase 3
- University of Maryland, Baltimore
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
Nagre-recruitPhase 2
- MedStar Franklin Square Medical Center ( Site 0033), Baltimore
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Nagre-recruitPhase 3
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC
Nagre-recruitPhase 1/2
- Johns Hopkins University, Baltimore
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
Nagre-recruitPhase 1
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Nagre-recruitPhase 1
- Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Nagre-recruitPhase 1
- Sidney Kimmel Comprehensive Cancer at Johns Hopkins, Baltimore
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Nagre-recruitPhase 1/2
- University of Maryland, Baltimore
A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
Nagre-recruitPhase 2
- Research Site, Baltimore
GCC 2546- Motion Management
Nagre-recruit
- University of Maryland Greenebaum Cancer Center, Baltimore
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Nagre-recruitPhase 1
- Advanced Molecular Imaging and Therapy, Glen Burnie · 9 mi ang layo
- United Theranostics - Chesapeake, Glen Burnie · 9 mi ang layo
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Nagre-recruitPhase 1
- Johns Hopkins Hospital /ID# 254056, Baltimore
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Nagre-recruitPhase 2
- Kaiser Permanente-Woodlawn Medical Center, Baltimore
- Kaiser Permanente Lutherville - Timonium Medical Center, Lutherville · 9 mi ang layo
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Nagre-recruitPhase 1
- Johns Hopkins University, Baltimore
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Nagre-recruitPhase 1/2
- Johns Hopkins Hospital, Baltimore
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Nagre-recruitPhase 1/2
- Johns Hopkins University, Baltimore
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Nagre-recruitPhase 3
- Research Site, Baltimore
A Study Evaluating Neoadjuvant Chemoimmunotherapy With Immunosensitizing Radiation for Borderline Resectable Non-Small Cell Lung Cancer
Nagre-recruitPhase 1
- Maryland Proton Treatment Center, Baltimore
- University of Maryland Greenebaum Cancer Center, Baltimore
- Baltimore Washington Medical Center- Tate Cancer Center, Glen Burnie · 9 mi ang layo
- at 1 pa
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Nagre-recruitPhase 2/3
- Saint Agnes Hospital, Baltimore
- Kaiser Permanente-Woodlawn Medical Center, Baltimore
- Kaiser Permanente Lutherville - Timonium Medical Center, Lutherville · 9 mi ang layo
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Nagre-recruitPhase 2
- Kaiser Permanente-Woodlawn Medical Center, Baltimore
- Kaiser Permanente Lutherville - Timonium Medical Center, Lutherville · 9 mi ang layo
Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
Nagre-recruitPhase 2
- University of Maryland Medical Center, Baltimore
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Nagre-recruitPhase 1/2
- Johns Hopkins University, Baltimore
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
Nagre-recruitPhase 1
- Research Site, Baltimore
KRAS-Targeted Vaccine With Chemoimmunotherapy, Nivolumab and Ipilimumab for Patients With NSCLC
Nagre-recruitPhase 1
- Johns Hopkins University, Baltimore
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Nagre-recruitObservasyonal na pag-aaral
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- UM Saint Joseph Medical Center, Towson · 8 mi ang layo
- at 1 pa
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
Nagre-recruitPhase 2
- Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore
- Harry and Jeannette Weinberg Cancer Institute at Franklin Square, Baltimore
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
Nagre-recruit
- Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD, Baltimore
GEMINI-NSCLC: NSCLC Biomarker Study
Nagre-recruitObservasyonal na pag-aaral
- University of Maryland, Baltimore
- Johns Hopkins University, Baltimore
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Nagre-recruitObservasyonal na pag-aaral
- Massive Bio SYNERGY-AI site, Baltimore
- Massive Bio SYNERGY-AI site, Towson · 8 mi ang layo
First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
Nagre-recruitPhase 1
- University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
Pag-aaral para sa Non-Small Cell Lung Cancer sa ibang lungsod
- Houston, TX145 pag-aaral
- New York City, NY121 pag-aaral
- Arlington, VA104 pag-aaral
- Nashville, TN97 pag-aaral
- Boston, MA90 pag-aaral
- Los Angeles, CA87 pag-aaral
- St. Louis, MO73 pag-aaral
- Chicago, IL61 pag-aaral
- San Antonio, TX59 pag-aaral
- Columbus, OH57 pag-aaral
- Washington, DC55 pag-aaral
- Seattle, WA53 pag-aaral
Iba pang pag-aaral sa Baltimore
- Kanser sa Suso47 pag-aaral
- Kanser sa Prostate43 pag-aaral
- Kanser sa Baga40 pag-aaral
- Kanser (lahat ng uri)37 pag-aaral
- Kanser sa Pancreas31 pag-aaral
- Colorectal Cancer31 pag-aaral
- Metastatic Cancer28 pag-aaral
- Obesity26 pag-aaral
- Kanser sa Pantog24 pag-aaral
- Pagkabigo ng Puso24 pag-aaral
- Kanser sa Ovary22 pag-aaral
- Stroke21 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.